Determinants of fasting and post-methionine homocysteine levels in families predisposed to hyperhomocysteinemia and premature vascular disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 5, 1999, Pages 1316-1324

  De Jong, S C ^a,b   Stehouwer, C D A ^a,b,c   Van Den Berg, M ^a,b   Kostense, P J ^d   Alders, D ^a   Jakobs, C ^a,c   Pals, G ^a   Rauwerda, J A ^a,b  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Familial hyperhomocysteinemia; Homocysteine; Methionine loading test; Methylenetetrahydrofolate reductase; Premature vascular disease; Vitamins

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CREATININE; FOLIC ACID; HOMOCYSTEINE; METHIONINE;

ADULT; ALLELE; ARTICLE; ATHEROSCLEROSIS; DIET RESTRICTION; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING;

EID: 0032943256     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.5.1316     Document Type: Article

References (51)

1. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-1155.
2. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230-236.
3. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, Palma-Reis RJ, Boers GHJ, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Lúis AC, Parrot-Roulaud FM, Soon Tan K, Higgins I, Garcon D, Medrano MJ, Candito M, Evans AE, Andria. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997;277:1775-1781.
4. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274: 1049-1057.
5. Bostom AG, Jacques PF, Nadeau MR, Williams RR, Ellison RC, Selhub J. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from The NHLBI Family Heart Study. Atherosclerosis. 1995;116:147-151.
6. De Jong SC, Stehouwer CDA, Mackaay AJC, van den Berg M, Bulterijs EJ, Visser FC, Bax J, Rauwerda JA. High prevalence of hyperhomocysteinemia and asymptomatic vascular disease in siblings of young patients with vascular disease and hyperhomocysteinemia. Arterioscler Thromb Vasc Biol. 1997;17:2655-2662.
7. Van den Berg M, Stehouwer CDA, Bierdrager E, Rauwerda JA. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol. 1996; 16:165-171.
8. 6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia. J Vasc Surg. 1994;20:933-940.
9. Harmon DL, Woodside JV, Yarnell JWG, McMaster D, Young IS, McCrum EE, Gey KF, Whitehead AS, Evans AE. The common 'thermolabile' variant of methylenentetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. Q J Med. 1996;89: 571-577.
10. Rozen R. Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb Haemost. 1997; 78:523-526.
11. Bates CJ, Mansoor MA, van der Pols J, Prentice A, Cole TJ, Finch S. Plasma total homocysteine in a representative sample of 972 British men and women aged 65 and over. Eur J Clin Nutr. 1997;51:691-697.
12. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7-9.
13. Engbersen AMT, Franken DG, Boers GHJ, Stevens EMB, Trijbels FJM, Blom HK. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet. 1995;56: 142-150.
14. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EMB, van Oost BA, den Heijer M, Trijbels FJM, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996;58:35-41.
15. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GHJ, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10: 111-113.
16. de Franchis R, Mancini FP, D'Angelo A, Sebastio G, Fermo I, de Stefano V, Margaglione M, Mazzola G, di Minno G, Andria G. Elevated total plasma homocysteine and 677 C→T mutation of the 5,10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease. Am J Hum Genet. 1996;59:264-268.
17. Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. Circulation. 1996;94:1812-1814.
18. Schwartz SM, Siscovick DS, Malinow MR, Rosendaal FR, Beverly RK, Hess DL, Psaty BM, Longstreth WT, Koepsell TD, Raghunathan TE, Reitsma PH. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation. 1997;96:412-417.
19. Ma J, Stampfer MJ, Hennnekens CH, Frosst P, Selhub J, Horsford J, Malinow MR, Willett JWC, Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine and risk of myocardial infarction in US physicians. Circulation. 1996;94:2410-2416.
20. Kang SS, Passen EL, Ruggie N, Wong PWK, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1993;88:1463-1469.
21. Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Goyette P, Rosenblatt DS, Genest J, Rozen R. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vase Biol. 1997;17:569-573.
22. Guttormsen AB, Ueland PM, Nesthus I, Nygård O, Schneede J, Vollset SE, Refsum H. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥40 μmol/liter). The Hordaland Homocysteine Study. J Clin Invest. 1996;98:2174-2183.
23. Kang SS, Wong PWK, Zhou J, Sora J, Lessick M, Ruggie N, Grcevich G. Thermo-labile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism. 1988;37:611-613.
24. Malinow MR. Homocyst(e)ine and arterial occlusive diseases (Frontiers in Medicine). J Intern Med. 1994;236:603-617.
25. Nygård O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland PM, Kvåle G. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA. 1995;274: 1526-1533.
26. Franken DG, Boers GHJ, Blom HJ, Cruysberg JRM, Trijbels FJM, Hamel BCJ. Prevalence of familial mild hyperhomocysteinemia. Atherosclerosis. 1996;125:71-80.
27. Williams RR, Malinow MR, Hunt SC, Upson B, Wu LL, Hopkins PN, Stults B, Kuida H. Hyperhomocyst(e)inemia in Utah siblings with early coronary disease. Coron Artery Dis. 1990;1:681-685.
28. Wu LL, Wu J, Hunt SC, James BC, Vincent GM, Williams RR, Hopkins PN. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem. 1994;40:552-561.
29. Genest JJ, McNamara JR, Upson B, Salem DN, Ordovas JM, Schaefer EJ, Malinow MR. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb. 1991;11: 1129-1136.
30. Malinow MR, Nieto FJ, Kruger WD, Duell PB, Hess DL, Gluckman RA, Block PC, Holzgang CR, Anderson PH, Seltzer D, Upson B, Lin QR. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol. 1997;17:1157-1162.
31. Te Poele-Pothoff MTWB, van den Berg M, Franken DG, Boers GHJ, Jakobs C, de Kroon IFI, Eskes TABK, Trijbels JMF, Blom HJ. Three different methods for the determination of total homocysteine in plasma. Ann Clin Biochem. 1995;32:218-220.
32. Ubbink JB, Serfontein WJ, de Villiers LS. Stability of pyridoxal-5-phosphate semicarbazone; applications in plasma vitamin B6 analysis and population surveys of vitamin B6 nutritional status. J Chromatogr. 1985; 342:277-284.
33. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
34. Verhoef P, Kok FJ, Kluijtmans LAJ, Blom HJ, Refsum H, Ueland PM, Kruyssen DACM. The 677 C→T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis. 1997;132: 105-113.
35. Gallagher PM, Meleady R, Shields DC, Tan KS, McMaster D, Rozen R, Evans A, Graham IM, Whitehead AS. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation. 1996;94:2154-2158.
36. Van Bockxmeer FM, Mamotte CDS, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 1997;95:21-23.
37. Brugada R, Marian AJ. A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. Atherosclerosis. 1997;128:107-112.
38. Bostom AG, Gohh RY, Tsai MY, Hopkins-Garcai BJ, Nadeau MR, Bianchi LA, Jacques PF, Rosenberg IH, Selhub J. Excess prevalence of fasting and postmethionine-loading hyperhomocysteinemia in stable renal transplant recipients. Arterioscler Thromb Vasc Biol. 1997;17: 1894-1900.
39. Andersson A, Brattström L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest. 1992;22:79-87.
40. Wouters MGAJ, Moorrees MTHEC, Van der Mooren MJ, Blom HJ, Boers GHJ, Schellekens LA, Thomas CMG, Eskes TKAB. Plasma homocysteine and menopausal status. Eur J Clin Invest. 1995;25:801-805.
41. Boers GH, Smals AG, Trijbels FJ, Leermakers AI, Kloppenborg PW. Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest. 1983;72:1971-1976.
42. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693-2698.
43. Brattström L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B. Hyperhomocysteinemia in stroke: prevalence, cause and relationships to type of stroke and stroke risk factors. Eur J Clin Invest. 1992;22:214-221.
44. Brattström L, Israelsson B, Norrving B, Bergqvist D, Thörne J, Hultberg B, Hamfelt A. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis. 1990;81:51-60.
45. Miller JW, Nadeau MR, Smith D, Selhub J. Vitamin B-6 deficiency vs folate deficiency: comparison of responses to methionine loading in rats. Am J Clin Nutr. 1994;59:1033-1039.
46. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. New York, NY: McGraw-Hill; 1995; 1279-1327.
47. Ubbink JB, van de Merve A, Delport R, Allen RH, Stabler SP, Riezler R, Vermaak WJ. The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest. 1996;98:177-184.
48. 13C]methionine as a tracer. Am J Clin Nutr. 1991;54:377-385.
49. Nygård O, Refsum H, Ueland PM, Stensvold I, Nordrehaug JE, Kvåle G, Vollset SE. Coffee consumption and plasma total homocysteine: The Hordaland Homocysteine Study. Am J Clin Nutr. 1997;65: 136-143.
50. Mansoor MA, Kirstensen O, Hervig T, Drablos PA, Stakkestad JA, Woie L, Hetland O, Osland A. Low concentrations of folate in serum and erythrocytes of smokers: methionine loading decreases folate concentrations in serum of smokers and nonsmokers. Clin Chem. 1997;43: 2192-2194.
51. Loehrer FMT, Haefeli WE, Angst CP, Browne G, Frick G, Fowler B. Effect of methionine loading on 5-methyltetrahydrofolate, S-adenosylmethionine and S-adenosylhomocysteine in plasma of healthy humans. Clin Sci (Colch). 1996;91:79-86.